Evidence map›Paper›PMID 42173947›Full record

ArticleScientific reports2026

New hybrid pyridine-1,2,4-triazole scaffolds: synthesis, in vitro evaluation of anticancer and antimicrobial activity, and in silico insights.

Aida Šermukšnytė, Dainius Lukauskas, Maryna Stasevych, Viktor Zvarych, Olena Komarovska-Porokhnyavets, Kristina Kantminienė, Ingrida Tumosienė, Vilma Petrikaitė

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aida Šermukšnytė *Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, Kaunas, 50254, Lithuania.
Dainius Lukauskas *Department of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, 50162, Lithuania.
Maryna StasevychDepartment of Technology of Biologically Active Substances, Pharmacy, and Biotechnology, Lviv Polytechnic National University, S. Bandera Str. 12, Lviv, 79013, Ukraine.
Viktor ZvarychDepartment of Automated Control Systems, Lviv Polytechnic National University, S. Bandera Str. 12, Lviv, 79013, Ukraine.
Olena Komarovska-PorokhnyavetsDepartment of Technology of Biologically Active Substances, Pharmacy, and Biotechnology, Lviv Polytechnic National University, S. Bandera Str. 12, Lviv, 79013, Ukraine.
Kristina KantminienėDepartment of Physical and Inorganic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, Kaunas, 50254, Lithuania. kristina.kantminiene@ktu.lt.
Ingrida TumosienėDepartment of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, Kaunas, 50254, Lithuania.
Vilma PetrikaitėDepartment of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, 50162, Lithuania. vilma.petrikaite@lsmu.lt.

Funding

Research Council of Lithuania (LMTLT) S-MIP-25-22
6 · The paper itself

Abstract

1,2,4-Triazole-3-thiones bearing 2-amino-5-chloropyridine or 2-amino-3,5-dibromopyridine moieties were S-alkylated with substituted bromoacetamides to obtain target 1,2,4-triazole-3-thiols. Anticancer effects of the synthesized compounds were evaluated in vitro using cell monolayer (MTT and 'wound healing' assays) and 3D spheroid models against human lung adenocarcinoma (A549), triple-negative breast cancer (MDA-MB-231), and melanoma (IGR39) cell lines. In the initial screening, compounds incorporating the 3,5-dibromopyridyl fragment were generally the most cytotoxic and compound 34 (5-chloropyridinyl derivative) was the most potent, with EC

Indexed as

Anti-Infective AgentsAntineoplastic AgentsPyridinesTriazolesCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansMolecular Docking Simulation1,2,4-triazoleAnti-Infective AgentsAntineoplastic AgentsPyridinesTriazolesAcetamideAntimicrobial activityCell migrationCell viabilitySelectivityTumour spheroids

Identifiers

PMID42173947
PMCPMC13526864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.